The Jadelle Access Program will ensure that Jadelle®, an effective, long-acting, reversible contraceptive implant, is going to be available to more than 27 million women in the world's poorest countries at a more than 50 percent price reduction over the next six years. The Jadelle Access Program – developed and supported through a partnership between Bayer HealthCare AG, the Bill & Melinda Gates Foundation, the Clinton Health Access Initiative (CHAI), the Governments of Norway, the United Kingdom, the United States and Sweden, and the Children’s Investment Fund Foundation (CIFF) and the United Nations Population Fund (UNFPA) – builds on momentum generated at the July 2012 London Summit on Family Planning, where global leaders pledged to provide an additional 120 million women in developing countries with contraceptive access by 2020.
It also supports the recommendations of the UN Commission on Life-Saving Commodities by helping to shape global markets in order to increase the availability of quality, life-saving commodities at an optimal price and volume. When fully implemented, the Jadelle Access Program will avert more than 28 million unintended pregnancies between 2013 and 2018, and, ultimately, prevent approximately 280,000 infant and 30,000 maternal deaths. In total, the program will save an estimated US$250 million in global health costs.